[{"id":"495b5eb1-f870-47b8-a171-3b0065ad59ef","acronym":"CT0180-CG1203","url":"https://clinicaltrials.gov/study/NCT04756648","created_at":"2021-02-16T12:53:54.114Z","updated_at":"2024-07-02T16:35:42.852Z","phase":"Phase 1","brief_title":"Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma","source_id_and_acronym":"NCT04756648 - CT0180-CG1203","lead_sponsor":"Zhejiang University","biomarkers":" PD-L1 • GPC3","pipe":"","alterations":" ","tags":["PD-L1 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CT0180"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-07-17"},{"id":"1d6660e2-1c5f-4568-b402-d32f87fd42b8","acronym":"CISLD-4","url":"https://clinicaltrials.gov/study/NCT03980288","created_at":"2021-01-19T18:10:57.427Z","updated_at":"2024-07-02T16:35:56.757Z","phase":"Phase 1","brief_title":"4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3","source_id_and_acronym":"NCT03980288 - CISLD-4","lead_sponsor":"Zhejiang University","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CT0180"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 07/23/2019","start_date":" 07/23/2019","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2023-01-31"},{"id":"3baeb9f0-bd85-4678-b781-4c26ea875afb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03884751","created_at":"2021-03-26T10:27:09.628Z","updated_at":"2024-07-02T16:36:16.716Z","phase":"Phase 1","brief_title":"Chimeric Antigen Receptor T Cells Targeting Glypican-3","source_id_and_acronym":"NCT03884751","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CT0180"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 08/15/2019","start_date":" 08/15/2019","primary_txt":" Primary completion: 05/28/2021","primary_completion_date":" 05/28/2021","study_txt":" Completion: 12/03/2021","study_completion_date":" 12/03/2021","last_update_posted":"2022-02-24"},{"id":"08310589-48de-424e-82b3-d1923ffca137","acronym":"","url":"https://clinicaltrials.gov/study/NCT03302403","created_at":"2021-01-18T16:18:51.239Z","updated_at":"2024-07-02T16:36:40.277Z","phase":"","brief_title":"Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors","source_id_and_acronym":"NCT03302403","lead_sponsor":"Kang YU","biomarkers":" CLDN18 • GPC3","pipe":" | ","alterations":" CD19 positive • GPC3 positive","tags":["CLDN18 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • satricabtagene autoleucel (CT041) • CT011 • CT0180 • CT032 • cyclophosphamide intravenous • zevorcabtagene autoleucel (CT053)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/29/2017","start_date":" 12/29/2017","primary_txt":" Primary completion: 12/12/2020","primary_completion_date":" 12/12/2020","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2020-10-08"},{"id":"bb14f754-057f-42b3-a78b-090a95232262","acronym":"","url":"https://clinicaltrials.gov/study/NCT03146234","created_at":"2021-01-19T14:08:15.002Z","updated_at":"2024-07-02T16:36:56.215Z","phase":"","brief_title":"CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma","source_id_and_acronym":"NCT03146234","lead_sponsor":"RenJi Hospital","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CT0180"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 10/18/2018","primary_completion_date":" 10/18/2018","study_txt":" Completion: 10/18/2018","study_completion_date":" 10/18/2018","last_update_posted":"2019-08-28"},{"id":"a4e18afb-a3de-4870-9081-352daa6c3503","acronym":"","url":"https://clinicaltrials.gov/study/NCT02876978","created_at":"2021-03-26T08:29:47.315Z","updated_at":"2024-07-02T16:37:29.595Z","phase":"Phase 1","brief_title":"Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT02876978","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CT0180 • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2016-08-24"}]